T. Andrew Bowdle, MD, PhD

• Professor of Anesthesiology and Pharmaceutics
• Chief of the Division of Cardiothoracic Anesthesiology
• Department of Anesthesiology
• University of Washington
• Seattle, Washington

A similar bifunctional role has been described for the lectin receptor endosialin [175] allergy levels in chicago promethazine 25 mg line, which is expressed by stellate cells allergy testing labcorp proven promethazine 25 mg, but no therapeutics exploiting either of these targets has reached clinical testing allergy forecast wheaton il promethazine 25 mg purchase online. In addition to downregulating collagen assembly allergy testing blood generic promethazine 25 mg buy online, the approach may also lead to stellate cell apoptosis [177] allergy medicine covered by insurance order promethazine 25 mg online. Similarly, modulation of intracellular proteins including transcription factors remains an interesting but elusive target of antifibrotic therapy. Herbal therapies and products derived from natural compounds are commonly used in traditional Chinese medicine and are increasingly tested under controlled, scientifically rigorous conditions [179]. Some show promise of efficacy, in particular sho-saiko-to, Salvia miltiorrhiza, and a green tea polyphenol. Neutralization of proliferative, fibrogenic, contractile, and/or proinflammatory responses of stellate cells Significant advances in growth factor biology will benefit the treatment of hepatic fibrosis through the development of antagonists to cytokines and their receptors. Relaxin, a natural peptide hormone that mediates parturition, has been developed as an agent that decreases collagen synthesis by stellate cells and increases matrix degradation in vitro and in vivo. Stellate cells also express relaxin receptors, which might represent an attractive target for antagonism [181­183]. Bosentan, a mixed endothelin A and B receptor antagonist, has antifibrotic activity and reduces stellate cell activation in experimental hepatic fibrosis. Some hepatotoxicity has been observed in clinical trials in patients with pulmonary disease [185], however, which has dampened enthusiasm for use of endothelin antagonists in liver disease. Stimulation of stellate cell apoptosis, reversion, or senescence Attention is increasingly focused on how liver fibrosis regresses, and in particular the fate of activated stellate cells as fibrosis recedes. Mounting evidence indicates that either reversal of the activated stellate cell phenotype or stellate cell senescence and apoptosis all occur in vivo [186­188]. In particular, as liver fibrosis is decreased, there is selective cell death of activated stellate cells. More recently, two studies have documented reversion of activated stellate cells to a more quiescent, or inactivated state [186,187]. Another approach is to stimulate stellate cell clearance mediated by natural killer T cells. Experimental evidence supports this approach [190,191], which is now being translated into potential treatments. Similarly, activation of the inflammasome in stellate cells has been described [192], which could lead to other immunologic antifibrotic strategies. Since cross-linking may be a critical determinant of reversibility, inhibitors or crosslinking enzymes are being developed. One in particular, an antibody to the enzyme lysyl oxidase 2, showed excellent activity in animal models [196,197] and is currently undergoing extensive testing in patients with liver disease and other fibrotic disorders. Finally, efforts to amplify subsets of macrophages that are fibrolytic have a strong conceptual rationale, but are not yet sufficiently developed to yield new therapies. Future prospects Continued progress can be anticipated in unraveling the molecular regulation of fibrosis and its treatment. Rapid advances in gene therapy, tissue-specific targeting, and high-throughput small molecule screening of cytokine inhibitors are likely to benefit the diagnosis and therapy of hepatic fibrosis. New insights into the regulation of growth, apoptosis, and intracellular signaling by cytokines, adipokines, and hormones could have direct implications for stellate cell behavior in liver injury. Additionally, there is ongoing interest in herbal and natural antifibrotic remedies, particularly in East Asia, where many such compounds are undergoing clinical trials. Accelerating progress is certain once methods of noninvasive diagnosis are established that enable rapid assessment of fibrosis in clinical trials, and ultimately in clinical practice. Finally, knowledge gained from ongoing clinical trials continues to refine trial design and clarify endpoints for future studies. Degradation of scar matrix this component of treatment is very important because antifibrotic therapy in human liver disease will need to provoke resorption of existing matrix, in addition to preventing the deposition of new scar. Retinoids may also stimulate matrix degradation but concerns over toxicity limit their utility. Direct expression of metalloproteinases in animal models of hepatic fibrosis has begun to confirm that matrix can be resorbed through the expression of exogenous enzymes [193]. Sources of these enzymes may include macrophages as well as stellate cells [21,22,44], and stimuli to enhance their production are being sought, including antagonists to the galectin 1 receptor [194]. Endothelial cell-derived angiopoietin-2 controls liver regeneration as a spatiotemporal rheostat. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies. Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers. Hepatic stellate cells ­ protean, multifunctional, and enigmatic cells of the liver. Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial-mesenchymal transition in liver injury. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. Fibrogenesis in pediatric cholestatic liver disease:role of taurocholate and hepatocytederived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Steatosis and chronic hepatitis C:analysis of fibrosis and stellate cell activation. Extrahepatic platelet-derived growth factor-beta, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Induction of betaplatelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Adenosine induces loss of actin stress fibers and inhibits contraction in hepatic stellate cells via Rho inhibition. Collagen fibrillogenesis:fibronectin, integrins, and minor collagens as organizers and nucleators. Novel anti-fibrotic modalities for liver fibrosis:molecular targeting and regenerative medicine in fibrosis therapy. Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. The endocannabinoid system as a key mediator during liver diseases:new insights and therapeutic openings. Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Effects and regulation of connective tissue growth factor on hepatic stellate cells. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Coffee and caffeine are associated with decreased risk of advanced hepatic fibrosis among patients with hepatitis C. Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. Use of magnetic resonance elastography to assess hepatic fibrosis in children with chronic liver disease. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. Histologicalhemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. Spontaneous recovery from micronodular cirrhosis: Evidence for incomplete resolution associated with matrix cross-linking. Hepatic and serum lipid signatures specific to nonalcoholic steatohepatitis in murine models. Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosis. Hepatocyte growth factor suppresses profibrogenic signal transduction via nuclear export of Smad3 with galectin-7. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and-delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis. Hepatic stellate cell-expressed endosialin balances fibrogenesis and hepatocyte proliferation during liver damage. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest) and transient elastography (FibroScan(R)). Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. Protein fingerprinting of the extracellular matrix remodelling in a rat model of liver fibrosis ­ a serological evaluation. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. Prospective evaluation of FibroTest(R), FibroMeter(R), and HepaScore(R) for staging liver fibrosis in chronic hepatitis B: Comparison with hepatitis C. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Longterm Treatment Against Cirrhosis Trial. Deletion of the collagen-specific molecular chaperone Hsp47 causes endoplasmic reticulum stress-mediated apoptosis of hepatic stellate cells. A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. New insight into the anti-liver fibrosis effect of multitargeted tyrosine kinase inhibitors: from molecular target to clinical trials.

Calendula. Promethazine.

• How does Calendula work?
• Are there any interactions with medications?
• Muscle spasms, fever, cancer, nosebleeds, varicose veins, hemorrhoids, promoting menstruation, treating mouth and throat soreness, wounds, leg ulcers, and other conditions.
• Dosing considerations for Calendula.
• What is Calendula?
• Are there safety concerns?

Source: http://www.rxlist.com/script/main/art.asp?articlekey=96263

Chronic hepatitis is characterized by inflammation that is located predominantly in the portal areas allergy medicine cetirizine cheap promethazine 25 mg overnight delivery, with interface hepatitis (extension of inflammation beyond the limiting plate of hepatocytes surrounding the portal area) allergy testing mold buy discount promethazine 25 mg on line, and less prominent in the hepatic lobule; fibrosis may or may not be present allergy symptoms stiff joints promethazine 25 mg purchase with mastercard. The major inflammatory cell types are lymphocytes with occasional plasma cells and allergy treatment vitamin c promethazine 25 mg purchase without a prescription, rarely allergy medicine zyrtec dosage buy 25 mg promethazine with amex, eosinophils. The degree of inflammation and fibrosis may vary from mild to severe and is dependent on the stage of disease: inflammation is minimal in the immune tolerant and inactive phases but is a noticeable feature in the immune active phase. Liver fibrosis can vary from mild portal expansion to bridging fibrosis and cirrhosis. Ground-glass cells are not pathognomonic of hepatitis B and may be seen in other conditions such as drug-induced endoplasmic reticulum hypertrophy. Acute hepatitis B resolves without sequelae in 95% of immunocompetent adults but in only 5% of those infected during infancy. Acute liver failure is defined as the rapid development of hepatic encephalopathy (usually within 8 weeks) with severe impairment of hepatic synthetic function. It occurs in less than 1% of cases of acute hepatitis B but is associated with a high mortality rate. Spontaneous survival of acute fulminant hepatitis B without the requirement for liver transplantation is only approximately 20%. This phase is typically seen when the infection is acquired during infancy or early childhood (vertical transmission) and can last up to 2­4 decades. The immune tolerant phase is followed by the immune clearance or immune active phase. Establishing the phase of chronic infection is useful for advising patients of their prognosis and for making recommendations on the need for treatment. However, it is important to note that not all patients can be neatly classified into one of these defined phases and there will be patients who fall in between phases, termed "gray zones. The "first" phase is notable for very high viral replication but minimal liver injury and therefore has been termed the immune tolerant phase. This phase is only observed in persons who acquire the infection at birth or a young age. In one small retrospective study, the mean age of transition from the immune tolerant phase to another phase was 31 years over a median follow-up of 37 months [40]. Given the absence of a pronounced inflammatory response, the risk of disease progression to cirrhosis is considered to be low. In a paired liver biopsy study, 5 years apart, among persons in the immune tolerant phase, fibrosis progression was rare and no patient developed bridging fibrosis or cirrhosis [41]. The concept that individuals in this phase are "immune tolerant" has been challenged by recent studies demonstrating that the immune response in this phase does not 590 Part V: Viral Hepatitis demonstrate a "tolerogenic pattern" and is indistinguishable from that of persons in the immune active phase [42­45]. Simplistically, this phase can be viewed as a high-replication, noninflammatory phase of chronic infection. This phase is also characterized by high viral replication, but in contrast to the immune tolerant phase, hepatic inflammation is a prominent feature. Liver biopsy studies performed on inactive carriers show mild hepatic inflammation with varying degrees of fibrosis. One study of 116 inactive carriers, 58 of whom underwent liver biopsy reported that significant fibrosis (Knodell fibrosis stage >2) was detected in 8 (14%) of subjects [48]. However, other studies have generally reported mild fibrosis without cirrhosis [49] and a paired liver biopsy study of inactive carriers reported minimal fibrosis progression [50]. This latter finding may be partly explained by more severe liver fibrosis among older persons. The 5-year cumulative risk of cirrhosis was reported to range from 8% to 20% [58]. Whether these data pertain to persons with adult-acquired infection or those who are in the immune tolerant phase of infection is unknown. Diagnosis of acute and chronic hepatitis B cannot be established by the clinical presentation and requires specific serologic testing for viral antigens or host-produced antibodies. It may be seen as early as 1­2 weeks and as late as 11­12 weeks after exposure but is usually detectable 4­6 weeks before the onset of hepatitis. Hepatitis B core antigen is an intracellular antigen that is not secreted and consequently is not detectable in serum. Initially, it is of IgM class, which lasts for 4­6 months, after which it is replaced by IgG class. It is required for the establishment of acute infection and is thought to act as an immunological decoy. However, it can be detected in liver biopsy specimens in either a nuclear or cytoplasmic distribution. The issue can often be resolved if clinical features of chronic hepatitis are present, or if absent, by performing a liver biopsy and demonstrating histologic features or chronic hepatitis. It is rarely observed in persons from nonendemic regions, with a reported prevalence of 0. In contrast, it is more frequently detected in persons from endemic areas, with a prevalence of 10­20%. Role of liver biopsy the role of liver biopsy in management of chronic hepatitis B is declining with the availability of noninvasive tests of fibrosis. Traditionally, liver biopsy is used to grade (assess the amount of necro-inflammation) and stage (assess the amount of fibrosis, which is a surrogate for where the patient is in the natural history of the infection) the severity of liver disease and to exclude other causes of liver disease. Although liver biopsy is no longer routinely recommended in management of chronic hepatitis B, there are certain clinical situations where liver biopsy can provide valuable information, for example, as an aid in the decision to start antiviral therapy in patients without clear-cut indications for treatment, to investigate suspicious lesions detected on imaging, and to resolve discrepant results on noninvasive testing. Genotype A is prevalent in sub-Saharan and western Africa, northern Europe, and the United States, although they are of different subtypes: A1 and A3 are found in Africa, whereas A2 is found in northern Europe and the United States. Genotypes B and C are found predominantly in Central and Southeast Asia with different distributions of subtypes. Genotype D is mainly found in Africa, southern Mediterranean countries, and India. The lesser known genotypes F­J have very restricted geographical distributions, Table 24. Naturally occurring viral variants have been described for all four open reading frames. Naturally occurring and treatment-related variants may play role in the pathogenesis of liver disease, development of occult hepatitis B, and development of resistance to antiviral therapy. Mutations within the precore/core gene Mutations in the precore and basic core promoter regions of the precore/core gene are well described. The precore mutation is a single-nucleotide change G1896A that creates a translational stop codon. The basic core promoter mutations usually occur as two mutations ­ A1762T and G1764A ­ that inhibit viral transcription. A T­G base pair is inherently unstable and destabilizes epsilon, whereas the G1896A mutation stabilizes the stem­loop structure due to creation of the more stable T­A base pair. Precore and basic core promoter mutations were initially thought to be associated with the development of fulminant hepatitis [39,107,108], but this was not substantiated in other studies [109] and these variants have also been detected among inactive carriers and patients with minimal liver disease [110­112]. So exactly how these mutations may influence clinical outcome of acute and chronic hepatitis B is unclear. There is no convincing evidence that the precore or basal core promoter mutations influence response to interferon or nucelos(t)ide analog therapy [115,116]. Mutations within the s-gene Mutations in the pre-S and S regions of the surface gene have been reported. These mutations are though to affect important B- and T-cell epitopes and represent immune escape mutations. Variants that confer a replication advantage 598 Part V: Viral Hepatitis region that spans amino acid positions 124­149 of the small s-protein. Consequently, mutations in the polymerase gene may result in mutations in the surface gene and vice versa. Two notable mutations in the polymerase gene that occur as a result of antiviral resistance lead to mutations in the surface gene of clinical and biological relevance. The first is the rtV173L mutation, which is a compensatory mutation that arises to restore a decrease in replication fitness caused by the primary rtM204V/I antiviral resistance mutations. The other polymerase mutation is the adefovir-related resistance mutation rt181T that encodes for a stop codon within the overlapping s-gene at position sT172*. This mutation has been shown to result in decreased virion secretion and intracellular retention of the surface protein [125]. Mutations within the x-gene Single-point mutations and deletions of the 3 region of the x-gene have been described. In one study deletions of 3 region of the x-gene were more frequently observed in tumorous vs. Primary drug-resistant mutations are usually associated with a loss of viral fitness. Additional mutations may develop with continued use of the antiviral agent that restores viral fitness. A list of the major primary and secondary drug resistance mutations is provided in Table 24. Susceptibility to lamivudine is reduced by approximately 1000-fold with these mutations. The two most common secondary mutations associated with lamivudine therapy are V173L and L180M. The primary drug mutations associated with adefovir resistance include substitution of alanine by either threonine or valine at position 181 (rtA181T/V) and of asparagine by threonine at position 236 (rtN236T). These mutations decrease susceptibility to adefovir by approximately 5- to 10-fold and this is sufficient to result in virological breakthrough. The first mutation is either of the two lamivudine primary resistance mutations ­ rtM204V or rtM204I. These mutations decrease susceptibility to entecavir by approximately 10-fold and are not sufficient to cause antiviral resistance. This requires the development of a second mutation, rtT184A/C/F/G/I/L/M/S, rtS202C/G/I, or rt M250I/L/V. These mutations reduce susceptibility to entecavir by 10-fold and are unable to cause Domain C rtM204V/I rtM204I Domain D Domain E rtI169T, rtV173L, rtL180M, rtA181T, rtT184S rt181T/V rtA194T* rtI169T, T184A/C/F/G/I/L/M/S rt236T rtM204V/I rt202G/C/I M250I/L/V Chapter 24: Hepatitis B and D 599 resistance on their own. However, a combination of mutations reduces susceptibility to entecavir by >100-fold and leads to antiviral resistance to entecavir. From the clinical perspective, testing for antiviral resistance-associated variants prior to initiating treatment in a previously untreated patients is not required because these mutations are usually present at a low level and do not affect response to therapy with nucleos(t)ide analogs. However, testing is recommended prior to selection of rescue therapy in previously treated patients after development of antiviral resistance. Treatment is clearly indicated for individuals at greatest risk for these complications. Persons with advanced-stage fibrosis are at highest risk for complications and clearly benefit from viral suppression as was demonstrated in a randomized clinical trial [126]. The decision to initiate therapy requires careful consideration of the benefits and risks of therapy because of the known toxicity associated with interferon therapy and the requirement for long-term therapy with nucleos(t)ide analogs. Stopping therapy the discussion regarding treatment should also include the anticipated duration of therapy and the criteria for stopping therapy. This is most germane to the use of nucleos(t)ide analogs as peginterferon is administered for a finite period of time. Patients initiating therapy with nucleos(t)ide analogs should be made aware of the need for long-term therapy in the majority of cases. The endpoints of therapy are surrogate ones because clinical endpoints typically take decades to develop. Patients should be informed that this may not be a durable endpoint and therapy may need to be reinstituted. However, the relapse rate is high and the decision to stop therapy should be individualized and patients should be fully informed of the risks of hepatitis flares and hepatic decompensation following treatment discontinuation. However, only four drugs (peginterferon alfa, entecavir, tenofovir and tenofovir alafenamide) are considered first-line agents because of their efficacy and favorable resistance profiles [127]. Consequently, peginterferon has replaced standard interferon in most clinical situations. Patients were randomized to one of three treatment arms: peginterferon alfa-2a (180 g subcutaneously weekly) either alone or in combination with lamivudine 100 mg/day or lamivudine 100 mg/day alone for 48 weeks. Patients were randomized to receive peginterferon alfa-2a 90 g/week or 180 g/week for either 24 or 48 weeks. Higher doses of peginterferon were evaluated in the development program for peginterferon alfa-2a but were not shown to confer any greater efficacy over the 180 g per week dose [142]. In both arms the pegylated interferon dose was decreased to 50 g/week from weeks 32 to 52. In another study, 100 Chinese patients were randomized to receive either a combination of peginterferon alfa2b 1. In a multinational study, 552 patients were randomized to receive peginterferon alfa-2a monotherapy (180 g/week), or in combination with lamivudine (100 mg/day) or lamivudine (100 mg/day) alone for 48 weeks. Adverse effects of peginterferon therapy Peginterferon alfa-2a is associated with numerous adverse effects that often limit its tolerability. In clinical studies conducted among patients with chronic hepatitis B, approximately 5% of patients had to discontinue therapy and approximately 40% of patients required dose modification due to toxicity or side effects. The most common side effects experienced with peginterferon alfa-2a include flu-like symptoms such as fatigue, pyrexia, myalgia, headache, rigors, nausea, diarrhea, weight loss, and hair loss. Psychiatric adverse events are also common and range from mild symptoms such as irritability and anxiety to more serious events such as depression, psychosis and suicidal ideation/attempts. Other serious side effects of peginterferon include bone marrow suppression with cytopenias, increased risk of bacterial infections, development of autoimmune disorders including thyroiditis and ischemic conditions. Predictors of response to peginterferon Several host and virological factors assessed either at baseline or ontreatment have been identified with a better response to peginterferon therapy.

The survival of patients selected according to this definition exceeds 70% at 5 years allergy symptoms 8dpo purchase promethazine 25 mg with amex. Disease recurrence is around 10% and affects mostly peritoneal cavity allergy forecast phoenix az buy promethazine with american express, lymph nodes allergy shots utah order 25 mg promethazine visa, lung allergy symptoms to nuts buy discount promethazine on-line, and bones allergy symptoms in dogs skin purchase generic promethazine online. Recurrence is more frequent if pathology discloses vascular invasion (macro- or microscopic) or additional tumor nests, characteristics that are highly prevalent in tumors exceeding 5 cm [55]. Policies to prioritize patients continue to be refined to ensure equity between tumor and nontumor patients and to avoid the transplantation of patients with more aggressive disease and poor outcomes. No satellite nodules are observed and the vessels appear free of invasion at macro- and microscopic examination. The option that has raised most expectations is living donor liver transplantation. This requires a healthy donor to offer the right or left hepatic lobe to be implanted into the recipient. However, all these cohort studies are flawed by small sample size, short follow-up, and low applicability, and there is no reliable information regarding the impact of using the expanded criteria in the setting of scarce liver donations. Treatment is repeated on separate days and its efficacy is evaluated at 1 month by a dynamic imaging technique, where the absence of contrast uptake reflects tumor necrosis. The recurrence rate after percutaneous ablation is similar to that seen after surgical resection and presents as separate nodules occurring nearby or in separate liver segments [59]. Recently, microwave ablation has been utilized more frequently due to the application of higher temperatures leading to excellent local tumor control [62]. The absence of portal blood flow (portal vein obstruction, portosystemic anastomosis, or hepatofugal flow) is a contraindication for the procedure, which is also not indicated in patients with extrahepatic spread. Liver function should be preserved and this limits its application to patients in Child­Pugh class A. Hepatic artery obstruction requires an angiographic procedure with the advancement of a catheter into the hepatic artery in order to interrupt blood flow to the tumor as selectively as possible, thus limiting the injury of surrounding nontumor liver. The most common is Gelfoam prepared as 1 mm cubes, but active research is underway to develop more effective obstructing agents [63]. In this regard, a relevant advance has been the development of drug-eluting beads. These are particles that are loaded with chemotherapy as well as the embolization device to deliver the drug to the tumor without initial systemic washout release. This results in higher concentrations of drug over a longer time period reaching the tumor, with minimal systemic passage and, therefore, significantly fewer drug-related side effects [64]. The most frequent complication is the so-called "postembolization syndrome" that appears in nearly 50% of patients and consists of fever, abdominal pain, and a moderate degree of ileus. This is resolved in 48 hours and overlaps with the potential side effects of chemotherapy. Larger studies with survival as an endpoint are needed to determine which intra-arterial therapy is better. Additional sites are also recognized, and according to staging the appropriate treatment is chemoembolization. This combined therapy results in extensive tumor necrosis and improved patient survival. Over the last few years, a great deal of progress has been made in understanding the molecular alterations that condition tumor initiation and progression [70]. This has allowed the development of several agents that act on the molecular pathways in specific ways. Sorafenib basically acts by reducing angiogenesis and delaying cell proliferation. Sorafenib demonstrated a significant impact on survival (hazard ratio for survival compared with placebo of 0. The most common adverse events were diarrhea, weight loss, and hand/foot skin reactions. In most cases, the adverse events were mild and easy to manage so treatment was continued for 90% of subjects. Sorafenib has also been evaluated for treating subjects with compensated liver function (Child­Pugh class A); a recent study showed a safety profile in patients with Child­Pugh class B that was similar to those with Child­Pugh class A [72]. Regorafenib is an oral multikinase inhibitor that blocks the activity of protein kinases involved in angiogenesis, oncogenesis, metastasis, and tumor immunity. It has a distinct molecular target profile and more potent pharmacological activity than sorafenib [74]. Regorafenib was compared to placebo and it improved overall survival with a hazard ratio of 0. The most common grade 3 or 4 toxicities were hypertension, hand/foot skin reactions, fatigue, and diarrhea. An important recent development in cancer is the development of checkpoint inhibitors, which block a signal that would have prevented activated T cells from attacking cancer. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. The risk of endstage liver disease and hepatocellular carcinoma among persons infected with hepatitis C. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Ongoing studies will allow us to delineate pathways that will be translated into clinical medicine to allow us a personalized approach to the treatment of this tumor. Cancer mortality in East and Southeast Asian migrants to New South Wales, Australia, 1975­1995. International trends in liver cancer incidence, overall and by histologic subtype, 1978­2007. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Microwave coagulation therapy for hepatic tumors: review of the literature and critical analysis. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Hepatocelullar carcinoma: novel molecular approaches for diagnosis, prognosis and therapy. A surgical margin of 10 mm of bile duct is optimal, and intraoperative frozen sections of the bile duct are required to ensure a negative margin. It is well established that the risk of both local and distant recurrence after any treatment is significantly higher in patients with portal venous invasion, whether microscopic or macroscopic. Portal venous invasion should be considered a marker for a de-differentiated component of the tumor, portending an aggressive phenotype and high risk of recurrence. Size stability of a lesion smaller than 1 cm for 2 years allows less frequent surveillance, first every 6 months, then yearly. A negative biopsy result is reassuring, but the risk of false-negative biopsy of small lesions is not insignificant, so ongoing surveillance with cross-sectional imaging is recommended. In patients with an elevated bilirubin who have an elevated hepatic vein wedge pressure, surgical resection may result in liver decompensation, aside from small wedge resections. A reliable principle is this: patients with Child­Pugh A cirrhosis tolerate removal of 50% of their liver, and patients with Child­Pugh B tolerate removal of 25%. The morbidity and mortality of any liver resection in a patient with Child­Pugh C disease make it a contraindication to liver resection. There are other methods of assessing hepatic function, such as indocyanine green clearance, but these are not used widely in the United States. Local resource limitations, such as organ availability, and local practice patterns are also very important. Unfortunately, not all patients have access to liver transplant, so liver resection is a reasonable option that does offer some advantages. The primary advantage of liver resection is that there is no waiting time for a liver graft to become available. Survival of patients who undergo liver resection but who do not meet these two criteria is below 30% five years after resection [9]. Previously, anatomic resection based on Glissonian anatomy was thought to provide the best oncologic result. Given the need to minimize removal of functional liver tissue, and to reduce blood loss, nonanatomic resections have become more commonplace and do not appear to have a higher risk of recurrence. A margin of 5­10 mm appears to yield an acceptable oncologic result for the primary tumor. Left lobe tumors are generally removed through an upper midline incision, while right lobe lesions require a bilateral subcostal incision. For anatomical resection the hepatic artery, portal vein, and bile duct supplying the segment or lobe are identified and ligated. There are a number of techniques commonly used to minimize blood loss during liver resection. A large clamp with a broad area of compression, such as a Longmire clamp, can be used to compress the liver parenchyma during transection. Intermittent vascular inflow occlusion of the portal triad using a Pringle maneuver can be done during parenchymal division to reduce blood loss. Inflow can be occluded for short intervals, or up to 60 minutes in total, with low risk of significant liver injury from ischemia. Another strategy is the hanging liver technique, designed to facilitate an anterior approach to resection and reduce blood loss. This maneuver gets its name because vascular tape is passed under the liver anterior to the vena cava, and tension on the tape is used to elevate the liver. If these techniques are not sufficient, very rarely veno-venous bypass can be used. Portal vein embolization See also the section on Preoperative portal vein embolization in patients with cholangiocarcinoma.

High prevalence of hepatic focal nodular hyperplasia in subjects with hereditary hemorrhagic telangiectasia allergy testing uk reviews order generic promethazine line. Liver involvement in a large cohort of patients with hereditary hemorrhagic telangiectasia: echo-color-Doppler vs multislice computed tomography study allergy symptoms to nuts purchase promethazine 25 mg amex. Improvement of ischemic cholangiopathy in three patients with hereditary hemorrhagic telangiectasia following treatment with bevacizumab allergy testing anchorage purchase 25 mg promethazine mastercard. Congenital portosystemic shunts in children: a new anatomical classification correlated with surgical strategy allergy urticaria treatment order promethazine 25 mg without a prescription. Oral glutamine challenge and magnetic resonance spectroscopy in three patients with congenital portosystemic shunts allergy medicine gummies buy promethazine 25 mg without prescription. Sinusoidal dilatation and congestion in liver biopsy: is it always due to venous outflow impairment Peliosis hepatis with initial presentation as acute hepatic failure and intraperitoneal hemorrhage in children. Study of portal vein thrombosis in patients with idiopathic portal hypertension in Japan. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury. Role of pharmacogenetics in hematopoietic stem cell transplantation outcome in children. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stemcell transplantation: an open-label, phase 3, randomised controlled trial. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multiorgan failure. Nonetheless, during acute and severe arterial hypotension, shock, or hemodynamic instability, hepatic perfusion may become compromised resulting in ischemic hepatic injury. Zone 3 of the hepatic lobule is the most susceptible to ischemic damage, but in severe cases the histology may reveal extension of the hepatocellular necrosis into zone 2 and even periportal areas. In typical cases, serum aminotransferases rapidly increase within a few days, followed by an equally prompt decline after the inciting hypotensive episode is resolved. Passive congestion of the liver caused by heart failure results in abnormal serum aminotransferases and may include elevated serum bilirubin and coagulopathy. Ascites may be a presenting feature of passive hepatic congestion, even in the absence of cirrhosis. Cirrhosis preexisting the ischemic injury may be particularly susceptible to ischemia, and acute-on-chronic liver failure may follow after severe hypotension or shock. The unique circulatory abnormalities of the Budd­Chiari syndrome include hepatocellular necrosis due to venous outflow obstruction. In severe Budd­Chiari syndrome with associated portal vein thrombosis, extensive hepatocellular necrosis with liver failure may result from the inability of the portal vein to serve as a secondary compensatory outflow tract from the liver. Hepatic arterial occlusion may result in ischemic cholangiopathy due to the exclusive arterial blood supply of the biliary ductal system. Hepatic infarction may result from occlusion of the main hepatic artery, particularly in the early postoperative period following liver transplantation. Hepatic infarction may also develop following pancreatic or biliary surgery due to inadvertent hepatic artery injury. The liver is abundantly perfused with blood from both the portal vein and hepatic artery. This dual blood supply mixes within the hepatic sinusoids and subsequently exits the liver through the three major hepatic veins. The dual blood supply dampens the effect of arterial hypotension or decreased cardiac output on the total hepatic blood flow. Nonetheless, marked and/or prolonged decreases in cardiac output or shock may lead to ischemic hepatic injury. Heart failure associated with arterial hypotension primarily affects arterial blood flow and oxygen delivery to the liver. If severe, this can lead to hepatocellular necrosis and prominent, at times towering, elevation in serum levels of liver-derived aminotransferases. Acute hepatic ischemic injury frequently occurs without affecting hepatic function or causing permanent liver damage. Less severe but chronic hepatic ischemia may exhibit mild to moderate elevations of aminotransferase levels but may lead to progressive hepatic fibrosis. Acute or chronic congestive heart failure causes elevated pressures in the vena cava and hepatic veins leading to passive hepatic congestion, ascites formation, and eventually the development of cirrhosis. Hepatic injury caused by circulatory failure may result in a broad array of biochemical, histologic, and pathophysiologic features. This article discusses liver injury related to acute ischemia, passive hepatic congestion, ischemic cholangiopathy, hepatic infarction, obstruction to the venous outflow of the liver, and heat stroke. Liver cells may also be injured, as reflected by abnormal liver chemistries, by many other disorders affecting hepatic blood flow such as immunologic diseases and vasculitides, which are discussed in other chapters. About two thirds of the dual blood supply of the liver enters the organ through the main portal vein. The portal blood is a low-pressure system that contains nutrients absorbed from the intestine, including glucose, amino acids, water-soluble vitamins, and triglycerides; it has a relatively low oxygen content [1]. The remaining one third of the liver blood flow is derived from the hepatic artery, an oxygen-rich high-pressure system. More than half of the oxygen delivered to the liver is supplied by the hepatic artery blood flow, which is also the only blood supply for the entire biliary ductal system. The liver, including the biliary ductal system, is susceptible to ischemic injury due to a reduction in hepatic arterial blood flow. A comparable decrease in portal blood flow is less likely to cause ischemic injury to the liver. Patients with portal vein thrombosis, in which the only hepatic blood supply is through the hepatic artery, are particularly susceptible to ischemic hepatic injury following a disruption in hepatic arterial blood flow. Each portal triad contains a small branch of the hepatic artery, portal vein, and one or two bile ducts. Sheets of hepatocytes, one to two cells thick and lined by hepatic sinusoids, extend between the portal triads and central vein. Both the portal and hepatic arterial blood enters the hepatic acinus through the portal tracts (zone 1 of the hepatic acinus in the Rappaport classification) and mixes within the hepatic sinusoids [2]. This admixed portal and arterial blood then flows to the center of the acinus (Rappaport zone 3) and ultimately exits the liver through the major hepatic veins. Therefore, zone 1 of the hepatic acinus contains oxygen- and nutrient-rich blood, and as blood flows through the sinusoids distally, it is progressively depleted of these components. Conversely, the zone 3 pericentral area receives less oxygen and is more susceptible to ischemic injury. The portal blood flowing into the liver is a low-pressure and relatively slow system, minimally affected by changes in systemic arterial blood pressure. In contrast, the hepatic arterial blood flow is a high-pressure system closely regulated to maintain a constant total hepatic blood flow (the sum of arterial and portal blood flows) [3]. Adenosine, a potent vasodilator of arterial smooth muscle cells, regulates hepatic arterial blood flow via local synthesis of nitric oxide. As portal blood flow increases, portal triad adenosine levels become diluted, leading to constriction of the hepatic arterioles and a decline in arterial blood flow [4,5]. The response of hepatic arterial smooth muscle to adenosine is not impaired in patients with cirrhosis. Ischemic hepatic injury Ischemic hepatic injury, previously termed ischemic hepatitis, is caused by reduced oxygen delivery leading to hepatocellular dysfunction and necrosis [6­10]. This form of hepatic injury is most often seen in the setting of severe arterial hypotension leading to global hepatic hypoperfusion. Events that cause abrupt and severe acute reductions in cardiac output (for instance, massive myocardial infarction, pulmonary embolus, or congestive heart failure) are common causes of ischemic hepatic injury. The functional subunit of the liver is the hepatic lobule or acinus, a roughly pentagonal-shaped structure with a central vein in the center and portal triads at each corner. Each portal triad contains a branch of the hepatic artery, portal vein, and bile duct. Sheets of hepatocytes extend between the central vein and portal triads at the edges of the lobule. Hepatic arterial and portal venous blood enters the acinus through the portal triad and then flows through hepatic sinusoids to the central vein. Zone 1 of the lobule lies at the periphery of the hepatic acinus (outer dashed circle). Portal tract Portal vein Sinusoid Bile duct Hepatic artery Zone 3 Central vein Sheets of hepatocytes Zone (A) (B) 1 Chapter 34: the Liver in Circulatory Failure 937 Box 34. Arterial hypotension r Cardiac failure Myocardial infarction Pulmonary embolus Exacerbation of congestive heart failure Cor pulmonale Pericardial tamponade r Hypovolemia Hemorrhage Dehydration Extensive burns r Miscellaneous Septic shock Heat stroke Sickle cell crisis Hypoxia r Acute respiratory failure r Acute exacerbation of chronic respiratory disease r Obstructive sleep apnea unless there is chronic congestion or hypoxia, or an underlying unrelated chronic liver disease. Features of both acute passive congestion and ischemic hepatic injury may be simultaneously present in patients with congestive heart failure experiencing episodic reductions in cardiac output and hypotension. Ischemic hepatic injury often resolves spontaneously following correction of the initial ischemic insult, with hepatocyte regeneration and a return to normal histology and liver function. However, in patients with chronic passive congestion and fibrosis, these abnormalities remain after resolution of the ischemic hepatic injury. Clinical features Most patients with ischemic hepatic injury do not develop signs or symptoms of liver disease such as jaundice, ascites, or encephalopathy, but exhibit changes confined to the liver biochemistries (see next paragraph). Patients with ischemic hepatic injury often have changes in mental status but this is rarely due to fulminant liver failure as a result of the ischemia. In a large prospective series, acute liver failure due to ischemic hepatic injury represented a very small proportion of cases (6%) [12]. Thus, true hepatic encephalopathy and associated hyperammonemia are uncommon in ischemic hepatic injury. In most cases, it is likely that the mental changes are related to the acute hypotensive event and hemodynamic derangements leading to cerebral hypoperfusion. The term shock liver is sometimes utilized when hepatic ischemic injury develops in the setting of severe hemodynamic instability. Pathophysiology the histologic hallmark of ischemic hepatic injury is zone 3 hepatocellular necrosis with little or no inflammatory response. Zones 3 and 2 show sinusoidal congestion with necrosis of the hepatocytes; in contrast, periportal sinusoids and hepatocytes are spared. In fact, ischemic hepatic injury is frequently associated with hypoxic or hypotensive injury to other organs, particularly the kidneys, as reflected by a rise in serum creatinine and other signs of acute kidney injury. The extent of serum bilirubin elevation is quite variable as it depends not only on the severity of the inciting event but also on the use of blood transfusions for resuscitation, associated hemolysis, and the presence of any underlying chronic liver disease. Serum ammonia is often elevated in these gravely ill patients with multiorgan failure but it is generally associated with a hypercatabolic state rather than acute hepatic failure. Furthermore, in the latter, aminotransferase levels gradually return to normal over several weeks rather than days. The systemic viremic syndrome (nausea, vomiting, anorexia, malaise, low-grade fever, and/or right upper quadrant discomfort), is absent in patients with hepatic ischemic injury. Nonetheless, acute hepatitis A, B, and C virus should be routinely excluded in patients with rapidly rising aminotransferases by the corresponding serologies. Inadvertent acetaminophen overdose is also an important differential diagnosis to keep in mind; the medical history and careful review of administered medications are key elements to identify this etiology. In the appropriate setting, causes of nonviral acute hepatitis such as Wilson disease and autoimmune hepatitis should be screened for as well. The hypotensive event leading to hepatic ischemic injury is often readily apparent, but is occasionally a transient event. In a large, recent meta-analysis of patients presenting with ischemic hepatic injury, the majority had predisposing cardiac factors and elevated cardiac filling pressures [13]. Venous congestion is a frequent companion of ischemic hepatic injury and should not be overlooked. In cirrhotic patients, ischemic hepatic injury may exhibit lesser aminotransferase elevations and lead to an acute-on-chronic episode of liver failure associated with a mortality greater than 60%. Outcomes are poor in patients with ischemic hepatic injury hospitalized in intensive care units, with only 50% patients surviving to discharge. The severity and prognosis of ischemic hepatic injury is worse in patients who develop jaundice. If the precipitating episode of ischemic hepatic injury persists, eventually irreversible multiorgan failure occurs. No specific drugs or agents promoting hepatic recovery from ischemia are available. Hepatic ischemia in the patient with cirrhosis the circulatory system is compromised in patients with cirrhosis in parallel with the severity of the liver dysfunction. A hyperdynamic circulatory state with relative arterial hypotension, peripheral arterial vasodilatation, and pooling of blood in the mesenteric splanchnic territory are characteristic of advanced cirrhosis.

Buy promethazine without prescription. 32 Food Allergy Thaggalante Emi Cheyali 1.

References

• Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961-72.
• Griffiths DJ, van Mastrigt R, Bosch R: Quantification of urethral resistance and bladder function during voiding, with special reference to the effects of prostate size reduction in urethral obstruction due to benign prostatic hyperplasia, Neurourol Urodyn 8:29n52, 1989.
• Pleskacova J, Hersmus R, Oosterhuis JW, et al: Tumor risk in disorders of sex development, Sex Dev 4(4n5):259n269, 2010.
• Subak LL, Waetjen LE, van den Eeden S, et al: Cost of pelvic organ prolapse surgery in the United States, Obstet Gynecol 98(4):646n651, 2001.
• Franchini M, Manzato F, Salvagno GL, et al. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review. Blood Coagulat Fibrinol. 2007;18(7):589-593.
• Bevans M. Changes in the musculature of the gastrointestinal tract and the myocardium in progressive muscular dystrophy. Arch Pathol 1945;40:225.
• Dogra VS, Gottlieb RH, Oka M, et al: Sonography of the scrotum, Radiology 227(1):18n36, 2003.
• Schultheiss, R., Doerffel, M. Standards for lithotripter performance. In: 2nd International Urolithiasis Research Symposium: 2008.